Autophagy triggered by magnolol derivative negatively regulates angiogenesis

Cell Death and Disease

Volumn 4, Issue 10, 2013, Pages

  Kumar, S ^a,b   Guru, S K ^a   Pathania, A S ^a,b   Kumar, A ^a   Bhushan, S ^a   Malik, F ^a,b  

^a CSIR INDIAN INSTITUTE OF INTEGRATIVE MEDICINE   (India)

^b ACADEMY OF SCIENTIFIC AND INNOVATIVE RESEARCH ACSIR   (India)

Author keywords

Angiogenesis; Autophagy; Hypoxia; Light chain protein 3; Vascular endothelial growth factor receptor 2

Indexed keywords

3 METHYLADENINE; ATG7 PROTEIN; MAGNOLOL; MICROTUBULE ASSOCIATED PROTEIN LIGHT CHAIN 3; PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CELL DEATH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG INHIBITION; FEMALE; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; AUTOPHAGY; BIPHENYL COMPOUNDS; CELL CYCLE; CELL DEATH; CELL LINE; CELL PROLIFERATION; COBALT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LIGNANS; MICROTUBULE-ASSOCIATED PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; PHENOLS; RATS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84887444217     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2013.399     Document Type: Article

References (43)

1. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: Differentiating stroma-poor tumors progress along an extra-adrenal chromaffin lineage. Lab Invest 1996; 75: 659-675
2. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362: 2202-2211
3. Laverdiere C, Cheung NK, Kushner BH, Kramer K, Modak S, LaQuaglia MP et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer 2005; 45: 324-332
4. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet 2007; 369: 2106-2120
5. Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011; 21: 229-237
6. Chesler L, Weiss WA. Genetically engineered murine models-contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Semin Cancer Biol 2011; 21: 245-255
7. Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D et al. The genetic landscape of high-risk neuroblastoma. Nat Genet 2013; 45: 279-284
8. Pant V, Quintas-Cardama A, Lozano G. The p53 pathway in hematopoiesis: Lessons from mouse models, implications for humans. Blood 2012; 120: 5118-5127
9. Zilfou JT, Lowe SW. Tumor suppressive functions of p53. Cold Spring Harb Perspect Biol 2009; 1: A001883
10. Meek DW. Tumour suppression by p53: A role for the DNA damage response? Nat Rev Cancer 2009; 9: 714-723
11. Dai C, GuW. p53 post-translational modification: Deregulated in tumorigenesis. Trends Mol Med 2010; 16: 528-536
12. Hainaut P, Hollstein M. p53 and human cancer: The first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137
13. Becker K, Marchenko ND, Maurice M, Moll UM. Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ 2007; 14: 1350-1360
14. Hosoi G, Hara J, Okamura T, Osugi Y, Ishihara S, Fukuzawa M et al. Low frequency of the p53 gene mutations in neuroblastoma. Cancer 1994; 73: 3087-3093
15. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-885
16. Hogarty MD. The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification. Cancer Lett 2003; 197: 173-179
17. Goldman SC, Chen CY, Lansing TJ, Gilmer TM, Kastan MB. The p53 signal transduction pathway is intact in human neuroblastoma despite cytoplasmic localization. Am J Pathol 1996; 148: 1381-1385
18. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013; 13: 83-96
19. Kruse JP, Gu W. Modes of p53 regulation. Cell 2009; 137: 609-622
20. Buschmann T, Fuchs SY, Lee CG, Pan ZQ, Ronai Z. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53. Cell 2000; 101: 753-762
21. Fuchs SY, Adler V, Buschmann T, Wu X, Ronai Z. Mdm2 association with p53 targets its ubiquitination. Oncogene 1998; 17: 2543-2547
22. de Rozieres S, Maya R, Oren M, Lozano G. The loss of mdm2 induces p53-mediated apoptosis. Oncogene 2000; 19: 1691-1697
23. Jones SN, Roe AE, Donehower LA, Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 1995; 378: 206-208
24. Montes de Oca Luna R, Wagner DS, Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 1995; 378: 203-206
25. Li M, Brooks CL, Kon N, Gu W. A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell 2004; 13: 879-886
26. Kon N, Kobayashi Y, Li M, Brooks CL, Ludwig T, Gu W. Inactivation of HAUSP in vivo modulates p53 function. Oncogene 2010; 29: 1270-1279
27. Altun M, Kramer HB, Willems LI, McDermott JL, Leach CA, Goldenberg SJ et al. Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes. Chem Biol 2011; 18: 1401-1412
28. Nakamura Y, Ozaki T, Niizuma H, Ohira M, Kamijo T, Nakagawara A. Functional characterization of a new p53 mutant generated by homozygous deletion in a neuroblastoma cell line. Biochem Biophys Res Commun 2007; 354: 892-898
29. Fan Y, Cheng J, Vasudevan SA, Patel RH, Liang L, Xu X et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis 2013; 18: 1224-1234
30. Mandinova A, Lee SW. The p53 pathway as a target in cancer therapeutics: Obstacles and promise. Sci Transl Med 2011; 3: 64rv61
31. Brown CJ, Cheok CF, Verma CS, Lane DP. Reactivation of p53: From peptides to small molecules. Trends Pharmacol Sci 2011; 32: 53-62
32. Pishas KI, Al-Ejeh F, Zinonos I, Kumar R, Evdokiou A, Brown MP et al. Nutlin-3a is a potential therapeutic for ewing sarcoma. Clin Cancer Res 2011; 17: 494-504
33. Yang Y, Ludwig RL, Jensen JP, Pierre SA, Medaglia MV, Davydov IV et al. Small molecule inhibitors of HDM2 ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 2005; 7: 547-559
34. Barbieri E, Mehta P, Chen Z, Zhang L, Slack A, Berg S et al. MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol Cancer Ther 2006; 5: 2358-2365
35. Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E et al. Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 2011; 14: 255-266
36. Manfredi JJ. The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev 2010; 24: 1580-1589
37. Nicholson B, Marblestone JG, Butt TR, Mattern MR. Deubiquitinating enzymes as novel anticancer targets. Future Oncol 2007; 3: 191-199
38. Daviet L, Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008; 90: 270-283
39. Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 2012; 22: 345-358
40. Reverdy C, Conrath S, Lopez R, Planquette C, Atmanene C, Collura V et al. Discovery of specific inhibitors of human USP7/HAUSP deubiquitinating enzyme. Chem Biol 2012; 19: 467-477
41. Zhang Y, Zhou L, Rouge L, Phillips AH, Lam C, Liu P et al. Conformational stabilization of ubiquitin yields potent and selective inhibitors of USP7. Nat Chem Biol 2013; 9: 51-58
42. Colland F, Formstecher E, Jacq X, Reverdy C, Planquette C, Conrath S et al. Small-molecule inhibitor of USP7/HAUSP ubiquitin protease stabilizes and activates p53 in cells. Mol Cancer Ther 2009; 8: 2286-2295
43. Patterson DM, Shohet JM, Kim ES. Preclinical models of pediatric solid tumors (neuroblastoma) and their use in drug discovery. Curr Protoc Pharmacol 2011; Chapter 14: Unit 14 17